Heart failure patients are classified by ejection fraction (EF) into distinct groups: heart failure with preserved ejection fraction (HFpEF) or heart failure with reduced ejection fraction (HFrEF). Although patients with heart failure commonly have multiple comorbidities that complicate management and may adversely affect outcomes, their role in the HFpEF and HFrEF groups is not well-characterized. This review summarizes the role of noncardiac comorbidities in patients with HFpEF versus HFrEF, emphasizing prevalence, underlying pathophysiologic mechanisms, and outcomes. Pulmonary disease, diabetes mellitus, anemia, and obesity tend to be more prevalent in HFpEF patients, but renal disease and sleepdisordered breathing burdens are similar. These comorbidities similarly increase morbidity and mortality risk in HFpEF and HFrEF patients. Common pathophysiologic mechanisms include systemic and endomyocardial inflammation with fibrosis.
METHODS

To identify additional relevant published data not discussed at the 10th Global CardioVascular Clinical
Trialists, we searched MEDLINE (via PubMed) from January 1994 to July 2014 (the Online Appendix presents the full search strategy). We used Medical Subject Headings and key words, focusing on the most relevant terms for this topic. We manually searched reference lists of pertinent reviews, including studies and background data to find any relevant citations that our searches might have missed. We imported all citations into an EndNote X7 database. One reviewer (J.P.K.) screened and evaluated the retrieved records to select relevant studies.
To focus on studies with representative patient samples, our search strategy required that publications included >500 patients and reported data from multiple sites. Given that entry criteria for clinical trials tend to exclude those with significant comorbidities, we focused on data from large HF registries and cohort studies. We required that the primary papers or supplemental materials include data on noncardiac comorbidities of interest.
In general, the prevalence of comorbidities was high across all studies, as demonstrated in the 3 largest U.S. HF registries (2, 10, 11) , as well as ambulatory HF populations in the United States (12, 13) , as discussed later in this review. Other world regions demonstrated findings similar to those seen in the United States (14) (15) (16) . Table 1 presents comorbidity prevalence data from several representative HF registries and epidemiological cohorts.
RESULTS
HFPEF VERSUS HFREF: DEMOGRAPHIC DIFFERENCES.
Overall, the data suggest that patients hospitalized with HFpEF tend to be 4 to 8 years older than those with HFrEF and are more often female ( Table 1) .
These observations are supported by an analysis from the Framingham Heart Study, which demonstrated that female sex was independently associated with a >2-fold increased risk for HFpEF versus HFrEF (17) .
Increasing age predicts both HFpEF and HFrEF, but the risk is significantly greater for HFpEF (18) . The sex differences in HF phenotype seem largely due to increased HFrEF in men related to previous myocardial infarction (18) . Another explanation for these findings relates to a differential response to hypertension in men versus women. Men tend to develop eccentric left ventricular (LV) hypertrophy in response to hypertension, whereas women tend to develop concentric LV hypertrophy (19) . Studies also found that African-American subjects have HFpEF less often than they have HFrEF (2, 10, 11) . These findings are counterintuitive due to the high prevalence of hypertension and LV hypertrophy in this population.
The specific reasons for these observations are unknown and require further investigation, but they may be related, in part, to ascertainment of the HFpEF diagnosis. It is unclear whether these findings are due (23) . The overall incidence of hospital admission is similar between the 2 groups, but HFpEF patients have a higher incidence of non-HF hospitalizations, whereas HFrEF patients have a higher incidence of HF hospitalizations (24) . Comorbidities, such as COPD, renal disease, and DM, are strongly associated with adverse outcomes in HF patients (25) .
HFpEF is not merely a disease of old age and multiple comorbidities but is a distinct entity associated with poor prognosis and severe cardiovascular dysfunction (26, 27) . However, few studies have explored the differential association between comorbidities and outcomes in HFrEF and HFpEF patients (24, (28) (29) (30) . In general, the increased risk for morbidity and mortality associated with these comorbidities is similar in those with HFpEF and HFrEF.
PATHOPHYSIOLOGY. The Central Illustration presents pathways linking several comorbidities to disease progression in both HFpEF and HFrEF. These comorbidities interrelate by several common mechanisms, including inflammation and activation of the sympathetic and renin-angiotensin-aldosterone systems (RAAS), as discussed later in this review. Ongoing smoking was also identified as an independent predictor of HFpEF, but not HFrEF, in epidemiological studies (18) , which supports the inflammatory hypothesis. However, further research is The primary effect of COPD seems to be increased noncardiovascular mortality during HF hospitalization (6), with similar outcomes in the early period after discharge (35). COPD is associated with increased long-term morbidity (36) and mortality (25) . 
CENTRAL I LLUSTRATION Associations Between HFpEF and HFrEF, With Comorbidities
Pathways linking several common comorbidities to disease progression in both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF) are presented, and factors exacerbating other comorbid conditions are highlighted. These comorbidities are interrelated by several common mechanisms, including inflammation and worsening congestion, as well as by sympathetic and renin-angiotensin-aldosterone system activation. Heart failure influences each of the comorbidities, demonstrating the bidirectional association. CV ¼ cardiovascular; LV ¼ left ventricular; RAAS ¼ renin-angiotensin-aldosterone system; RV ¼ right ventricular.
Mentz et al. A n e m i a . Comorbid anemia is more frequent in HFpEF patients than in HFrEF patients. Prevalence reports vary depending on the specific anemia definition used, but the trends are comparable. Contemporary studies tend to use the World Health Organization classification of anemia as hemoglobin <13 g/dl in men and <12 g/dl in women (24) . In the Get With The Guidelines Registry, there was an association between higher EF and increased prevalence of anemia (11) . The prevalence of anemia was 22% in patients with an EF $50%, 20% with EF 40% to 49%, and 14% with EF <40%, and there were also sexspecific differences (45). The prevalence of anemia tended to be higher in women in the setting of either include male sex and increased age (97, 98) . Elevated body mass index is an additional risk factor for OSA, whereas severe LV impairment and atrial fibrillation increase the likelihood of CSA (97, 99) . SDB is proinflammatory, with effects on oxidative stress and sympathetic activation (94) .
SDB has been associated with increased morbidity and mortality in the general population (100-102);
however, its impact on HF patient outcomes is less well defined. The majority of studies in HF patients focused on HFrEF patients, who had SDB that was an independent predictor of cardiac readmission (103) .
In 164 patients with chronic stable HFrEF, untreated
Mentz et al.
Comorbidities in HFpEF and HFrEF OSA was associated with increased mortality on multivariable analysis (104) . CSA was also shown to be a predictor of mortality in HFrEF (105). However, not all studies demonstrated a relationship between SDB and outcomes in HFrEF patients (106, 107) .
To our knowledge, no previous studies scrutinized a differential association between SDB and outcomes in HFrEF versus HFpEF patients. Studies to date in HFpEF patients generally assessed <200 patients, with the emphasis on describing prevalence and patient characteristics, rather than outcomes (95, 108) .
Thus, future research is needed to explore the impact of SDB on outcomes in HFpEF. SDB may represent a particularly important comorbidity in HFpEF patients, given the high prevalence of obesity in this patient population.
The primary treatment for OSA is nocturnal con- Trial protocols should consider feasibility of encouraging the inclusion of patients with comorbidities (as able). Trial sites should be selected partly on the basis of the comorbidity burden of the patient populations. Intensified safety monitoring may be needed in the context of comorbidities. Study entry criteria may need to be adjusted to acknowledge differences in biomarker thresholds in the context of comorbidities such as obesity and/or renal function. Exclusionary biomarker criteria (e.g., renal biomarkers) might offer mechanisms to support patient safety.
Comorbidities should be targeted, as able, as a primary intervention and include comorbidity-specific trial endpoints (e.g., dyspnea relief and beta-blocker usage in the context of chronic obstructive pulmonary disease [COPD] ). Trialists should also take into account regional differences in the prevalence of comorbidities when performing sample size calculations and designing trials (e.g., differential event rates in the presence of comorbid diseases). 
